Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVDL Avadel Pharmaceuticals	$9.50 -0.7%	$8.86	$6.38 ▼ $17.30	$919.02M	1.45	1.26 million shs	1.49 million shs
BCYC Bicycle Therapeutics	$8.04 -3.9%	$8.15	$6.10 ▼ $28.67	$556.80M	1.46	389,317 shs	149,458 shs
CRNX Crinetics Pharmaceuticals	$31.20 -1.8%	$31.23	$24.10 ▼ $62.53	$2.92B	0.28	846,075 shs	533,605 shs
IONS Ionis Pharmaceuticals	$35.24 -1.0%	$32.13	$23.95 ▼ $52.34	$5.61B	0.18	1.58 million shs	1.71 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVDL Avadel Pharmaceuticals	-0.73%	-5.66%	+5.44%	+10.08%	-39.91%
BCYC Bicycle Therapeutics	-3.94%	-5.85%	-0.74%	-15.99%	-65.19%
CRNX Crinetics Pharmaceuticals	-1.79%	-3.35%	-0.13%	-8.72%	-31.17%
IONS Ionis Pharmaceuticals	-0.98%	-4.13%	+5.01%	+6.95%	-13.31%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVDL Avadel Pharmaceuticals	2.3214 of 5 stars	3.5	1.0	0.0	3.4	1.7	0.6
BCYC Bicycle Therapeutics	3.5535 of 5 stars	4.4	1.0	0.0	2.8	4.2	0.6
CRNX Crinetics Pharmaceuticals	3.5411 of 5 stars	3.5	0.0	3.7	2.9	2.5	0.0
IONS Ionis Pharmaceuticals	4.3902 of 5 stars	4.3	2.0	3.0	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVDL Avadel Pharmaceuticals	3.00	Buy	$18.17	91.23% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$25.00	210.95% Upside
CRNX Crinetics Pharmaceuticals	2.91	Moderate Buy	$74.56	138.96% Upside
IONS Ionis Pharmaceuticals	2.68	Moderate Buy	$57.59	63.42% Upside

Current Analyst Ratings Breakdown

Latest CRNX, IONS, AVDL, and BCYC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	IONS Ionis Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$45.00 ➝ $48.00
5/20/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00 ➝ $50.00
5/8/2025	AVDL Avadel Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$19.00 ➝ $19.00
5/5/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Equal Weight ➝ Equal Weight	$15.00 ➝ $17.00
5/2/2025	BCYC Bicycle Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$35.00 ➝ $32.00
5/2/2025	BCYC Bicycle Therapeutics	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$17.00 ➝ $14.00
5/2/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$26.00 ➝ $22.00
5/2/2025	BCYC Bicycle Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$29.00 ➝ $29.00
5/1/2025	BCYC Bicycle Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $15.00
5/1/2025	IONS Ionis Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$65.00 ➝ $64.00
5/1/2025	IONS Ionis Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$45.00 ➝ $50.00

(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVDL Avadel Pharmaceuticals	$194.45M	4.73	N/A	N/A	$0.98 per share	9.69
BCYC Bicycle Therapeutics	$25.72M	21.65	N/A	N/A	$12.35 per share	0.65
CRNX Crinetics Pharmaceuticals	$760K	3,843.72	N/A	N/A	$8.07 per share	3.87
IONS Ionis Pharmaceuticals	$717.25M	7.82	N/A	N/A	$3.70 per share	9.52

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVDL Avadel Pharmaceuticals	-$160.28M	-$0.27	N/A	158.33	N/A	-52.53%	-93.34%	-44.77%	8/6/2025 (Estimated)
BCYC Bicycle Therapeutics	-$180.66M	-$3.14	N/A	N/A	N/A	-450.64%	-27.35%	-20.81%	8/5/2025 (Estimated)
CRNX Crinetics Pharmaceuticals	-$214.53M	-$3.82	N/A	N/A	N/A	N/A	-36.12%	-31.89%	8/6/2025 (Estimated)
IONS Ionis Pharmaceuticals	-$366.29M	-$2.99	N/A	N/A	N/A	-64.25%	-100.05%	-15.70%	7/30/2025 (Estimated)

Latest CRNX, IONS, AVDL, and BCYC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	CRNX Crinetics Pharmaceuticals	-$0.99	-$1.04	-$0.05	-$1.04	$0.10 million	$0.36 million
5/7/2025	Q1 2025	AVDL Avadel Pharmaceuticals	-$0.07	-$0.05	+$0.02	-$0.05	$50.57 million	$52.51 million
5/1/2025	Q1 2025	BCYC Bicycle Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$8.67 million	$9.98 million
4/30/2025	Q1 2025	IONS Ionis Pharmaceuticals	-$1.07	-$0.93	+$0.14	-$0.93	$144.31 million	$132.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVDL Avadel Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IONS Ionis Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVDL Avadel Pharmaceuticals	N/A	2.97	2.60
BCYC Bicycle Therapeutics	N/A	17.13	17.13
CRNX Crinetics Pharmaceuticals	N/A	16.39	16.38
IONS Ionis Pharmaceuticals	2.12	8.47	8.82

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVDL Avadel Pharmaceuticals	69.19%
BCYC Bicycle Therapeutics	86.15%
CRNX Crinetics Pharmaceuticals	98.51%
IONS Ionis Pharmaceuticals	93.86%

Insider Ownership

Company	Insider Ownership
AVDL Avadel Pharmaceuticals	4.80%
BCYC Bicycle Therapeutics	22.90%
CRNX Crinetics Pharmaceuticals	4.60%
IONS Ionis Pharmaceuticals	2.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVDL Avadel Pharmaceuticals	70	96.74 million	91.74 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	63.18 million	Optionable
CRNX Crinetics Pharmaceuticals	210	93.63 million	87.17 million	Optionable
IONS Ionis Pharmaceuticals	800	159.16 million	153.62 million	Optionable

CRNX, IONS, AVDL, and BCYC Headlines

Recent News About These Companies

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Acquired by GAMMA Investing LLC

June 17 at 3:14 AM | marketbeat.com

Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $48.00

June 14 at 2:53 AM | americanbankingnews.com

Ionis Treats First Patient in Phase III Antisense Oligonucleotide Trial in Angelman Syndrome

June 12, 2025 | precisionmedicineonline.com

Ionis announces Dr. Richard Geary, chief development officer, to retire; Dr. Holly Kordasiewicz to assume role in January 2026

June 12, 2025 | finance.yahoo.com

5IONS : Analyst Expectations For Ionis Pharmaceuticals's Future

June 12, 2025 | benzinga.com

JPMorgan Chase & Co. Raises Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $48.00

June 12, 2025 | marketbeat.com

First patient dosed in pivotal Phase 3 REVEAL clinical study of ION582 in Angelman syndrome

June 11, 2025 | finance.yahoo.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives $56.67 Average Target Price from Analysts

June 10, 2025 | americanbankingnews.com

Head-To-Head Comparison: Ionis Pharmaceuticals (NASDAQ:IONS) & Akero Therapeutics (NASDAQ:AKRO)

June 8, 2025 | americanbankingnews.com

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Given Average Recommendation of "Moderate Buy" by Brokerages

June 7, 2025 | marketbeat.com

California State Teachers Retirement System Acquires 7,722 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

June 3, 2025 | marketbeat.com

Why Is Ionis Pharmaceuticals (IONS) Up 5.5% Since Last Earnings Report?

May 30, 2025 | zacks.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $21.66 Million Stock Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

May 29, 2025 | marketbeat.com

Nuveen Asset Management LLC Trims Stake in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

May 29, 2025 | marketbeat.com

Voloridge Investment Management LLC Sells 63,698 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

May 27, 2025 | marketbeat.com

Woodline Partners LP Purchases New Position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

May 27, 2025 | marketbeat.com

D. E. Shaw & Co. Inc. Reduces Stock Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

May 26, 2025 | marketbeat.com

December 2027 Options Now Available For Ionis Pharmaceuticals (IONS)

May 25, 2025 | nasdaq.com

Ionis’ olezarsen shows new promise with strong Phase III results

May 23, 2025 | thepharmaletter.com

Ionis Pharmaceuticals (NASDAQ:IONS) Earns "Buy" Rating from HC Wainwright

May 22, 2025 | marketbeat.com

Two Sigma Advisers LP Boosts Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

May 22, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Quantum Stocks Skyrocket, Led by IonQ's NVIDIA Declaration
By Leo Miller | May 27, 2025
View Quantum Stocks Skyrocket, Led by IonQ's NVIDIA Declaration
As Oil Prices Rebound, These Stocks Could Fuel the Next Rally
By Sarah Horvath | June 9, 2025
View As Oil Prices Rebound, These Stocks Could Fuel the Next Rally
Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
By Leo Miller | May 19, 2025
View Buybacks and Big-Time Developments: 3 Stocks Making Huge Moves
Archer Aviation Stock Steadies After Short-Seller Report
By Jeffrey Neal Johnson | May 30, 2025
View Archer Aviation Stock Steadies After Short-Seller Report
AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!
By Thomas Hughes | June 16, 2025
View AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap!

CRNX, IONS, AVDL, and BCYC Company Descriptions

Avadel Pharmaceuticals NASDAQ:AVDL

$9.50 -0.07 (-0.73%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$9.60 +0.10 (+1.04%)

As of 04:19 AM Eastern

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Bicycle Therapeutics NASDAQ:BCYC

$8.04 -0.33 (-3.94%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$8.01 -0.03 (-0.44%)

As of 06/16/2025 07:57 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Crinetics Pharmaceuticals NASDAQ:CRNX

$31.20 -0.57 (-1.79%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$31.62 +0.42 (+1.35%)

As of 06/16/2025 05:25 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Ionis Pharmaceuticals NASDAQ:IONS

$35.24 -0.35 (-0.98%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$35.92 +0.68 (+1.94%)

As of 04:01 AM Eastern

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time